Though p53 can also regulate the DR5 gene [28], both ONC201/TIC10 [26] and brefledin A [29], which TIC9 is a prodrug of, possess p53-independent anti-cancer activity that suggests DR5 induction occurs through other transcription factors. Here, TP53 is linked to cancer.